Navigation Links
Mayo Clinic researchers find oncogene is important in pancreatic cancer growth and spread

JACKSONVILLE, Fla. Researchers at the Mayo Clinic campus in Florida have found that PKC-iota (PKC), an oncogene important in colon and lung cancers, is over-produced in pancreatic cancer and is linked to poor patient survival. They also found that genetically inhibiting PKC in laboratory animals led to a significant decrease in pancreatic tumor growth and spread.

The discovery, reported in the March 1 issue of Cancer Research, is especially encouraging, they say, because an experimental agent that targets PKC is already being tested in patients at Mayo Clinic.

"This is the first study to establish a role for PKC in growth of pancreatic cancer, so it is exciting to know that an agent already exists that targets PKC which we can now try in preclinical studies," says the study's senior investigator, Nicole Murray, Ph.D., of the Department of Cancer Biology.

The drug, aurothiomalate, is being tested in a phase I clinical trial in patients with lung cancer at Mayo Clinic's sites in Minnesota and Arizona. Based on findings to date, a phase II clinical trial is being planned to combine aurothiomalate with agents targeted at other molecules involved in cancer growth.

Mayo Clinic researchers, led by Alan Fields, Ph.D., chair of the Department of Cancer Biology and a co-author of this report, discovered aurothiomalate in 2006 by screening thousands of Food and Drug Administration-approved drugs for their ability to inhibit PKC signaling. The drug was once used to treat rheumatoid arthritis.

Dr. Murray stressed that this new study has not tested aurothiomalate against pancreatic cancer yet, but any treatment that targets this major cancer pathway offers a new avenue for therapy. "This is such a deadly disease. No standard treatment has shown much promise," she says. "New ideas and fresh, targeted therapies such as this are sorely needed."

Mayo researchers have led the field in understanding the role of the protein kinase C (PKC) family of enzymes as major players in cancer development and progression. Dr. Fields was the first to discover that PKC is a human oncogene an abnormal gene that cancer cells use to grow and/or survive. He found that PKC is genetically altered and over-expressed in a majority of lung cancers, and that over-expression of the gene in tumors predicts poor patient survival. That led to his search for aurothiomalate and the current testing in patients.

Dr. Murray says she has also found that different members of the PKC family play distinct roles in colon cancer, which offers more opportunity for targeted treatment. In fact, animal studies show that use of a different drug, enzastaurin, significantly reduced the initial development of colon tumors, according to Dr. Murray. Enzastaurin targets PKC-beta (PKC), which the Mayo team has shown is necessary for initiation of colon cancer, she says.

In the present study, the researchers looked at expression of PKC in pancreatic cancer because tumor studies show that a different gene, KRAS, is mutated up to 90 percent of the time, and KRAS regulates PKC. "KRAS has been very difficult to target therapeutically, which is why we are looking at molecules, such as PKC, that convey signals downstream of KRAS that can be manipulated," Dr. Murray says.

They found that PKC is highly expressed in most human pancreatic tumors they sampled, and that high PKC expression predicts poor patient survival. Studying patient tumors, they found that patients whose tumors exhibited high PKC expression had a median survival time of 492 days, compared to 681 days for low PKC expression, and a reduced five-year survival rate (10 percent versus 29.5 percent for low PKC expression).

The researchers then genetically manipulated the expression of PKC in pancreatic cancer cells. The results showed that PKC is required for the growth of pancreatic cancer in both cell-based and animal models. "This is the first demonstration that pancreatic tumors require PKC to grow and metastasize," Dr. Murray says.

The data suggest that aurothiomalate, which targets PKC, may be effective against pancreatic cancer either alone or in combination with other treatments, such as conventional chemotherapy. "Aurothiomalate may inhibit pancreatic cancer alone, or it may sensitize pancreatic tumors to chemotherapy," she says. "It is possible that a number of cancer growth pathways will need to be targeted for an effective therapy."


Contact: Paul Scotti
Mayo Clinic

Related medicine news :

1. Abington Memorial Hospital's Travelers Clinic Can Protect Travelers From The Now Active Yellow Fever
2. GE Healthcare, Intel and Mayo Clinic explore new models of health care delivery
3. Apex Heart Care, First Arizona Clinic to Install Shape-HF; New Medical Device Measures Patient Physiology to Define Shortness of Breath
4. At Risk Children Receive Free Dental Services at Communities In Schools Clinic
5. Spanish Only, Please: Special Latino Clinic Launched For Potential Abdominal Transplant Patients
6. Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World
7. International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Networks Big Biz Show February 22, 2010 at 1:40 pm PST
8. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
9. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
10. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
11. Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ProSidebar: ... in Final Cut Pro X. With ProSidebar: Fasion, video editors can easily add ... ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop zones, lines, ...
(Date:11/27/2015)... ... 27, 2015 , ... Consistent with the Radiology Business ... Better Radiology Marketing Programs meeting will showcase some of the best 2015 ... Caesars Palace in Las Vegas with a pre-conference session on a collaborative approach ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, ... interesting show that delves into an array of issues that are presently affecting Americans. ... from open dialogue, this show is changing the subjects consumers focus on, one episode ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Nov. 27, 2015  Lannett Company, Inc. (NYSE: ... completed the acquisition of Kremers Urban Pharmaceuticals Inc. ... global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... has acquired KU from UCB for total consideration ... including a customary working capital adjustment, a deduction ...
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... nuevo enfoque combina la inmunoterapia con la terapia fotodinámica ... Clinical Cancer Research . --> Clinical ...
(Date:11/26/2015)... 2015 --> --> ... to find optimal contrast weighting of MRI for patients ... signed a research agreement with SyntheticMR in order to use ... it is possible to generate multiple contrast images from a ... has left, thus making it possible to both fine tune ...
Breaking Medicine Technology: